NasdaqGM:KODBiotechs
Assessing Kodiak Sciences (KOD) Valuation After New KSI-101 Retinal Trial Updates
Kodiak Sciences (KOD) is back in focus after sharing new KSI-101 clinical data in Asian MESI patients at the AUS and ARVO meetings, reinforcing interest in its expanding retinal disease pipeline.
See our latest analysis for Kodiak Sciences.
The clinical updates around KSI-101 arrive after a sharp re-rating in Kodiak Sciences, with the share price at US$43.96 and a 90-day share price return of 82.33%, contributing to a very large 1-year total shareholder return, while the 5-year total...